0000000000535256

AUTHOR

Silvana Canevari

showing 3 related works from this author

Fisiopatologia. — Membrane vesicles, shed from in vitro cultured human breast carcinomas cells, inhibit lymphocytes proliferation.

1994

Membrane vesicles are released by the cells of the two human breast carcinoma cell lines 8701-BC and MCF-7. Vesicles express on their surface HLA Class I molecules and tumor associated antigens and they appear to have a strong, dose dependent, inhibitory effect on thymidine incorporation by periferal lymphocytes. Inhibition is evident on both PhA stimulated or non stimulated lymphocytes. The inhibitory effect is visible after three days of culture. Vesicle addition does not cause cytotoxic effects since inhibited lymphocytes are still capable to exclude Trypan blue. No apoptoptic cells were observed.

VesicleHuman leukocyte antigenBiologyMolecular biologyIn vitroTumor associated antigenCell biologychemistry.chemical_compoundchemistryGeneral Earth and Planetary SciencesCytotoxic T cellTrypan blueMembrane vesicleGeneral Agricultural and Biological SciencesHuman breastGeneral Environmental ScienceRendiconti Lincei
researchProduct

Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens.

1995

We have compared the pattern of surface antigen expression, as detected by monoclonal antibodies (mAbs), in plasma membranes vs shed membrane vesicles of two human breast carcinoma cell lines, MCF-7 and 8701-BC. Antigen expression was detected on cells by immunofluorescence (IF) analysis, whilst, due to their small dimensions, the same technique was not applicable to vesicles. For these structures dot-blot analysis and immunoelectron microscopy (IEM) were employed. When applicable, both cell membranes and membrane vesicles were immunoprecipitated and the precipitate (IP) was analyzed by SDS-PAGE. Cells of both lines expressed HLA class I antigens, epithelial cytokeratins, β1 integrins, CEA …

Cancer Researchmedicine.drug_classImmunoelectron microscopyCellBreast NeoplasmsMonoclonal antibodyImmunofluorescenceAntigenAntigens NeoplasmmedicineTumor Cells CulturedHumansMicroscopy Immunoelectronmedicine.diagnostic_testbiologyChemistryVesicleCarcinoma Ductal BreastCell MembraneGeneral MedicineMolecular biologyImmunohistochemistryCell biologyCulture MediaPleural Effusion MalignantMicroscopy Electronmedicine.anatomical_structureOncologyCell cultureAntigens SurfaceLiposomesbiology.proteinAntibodyExtracellular SpaceClinicalexperimental metastasis
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct